AU2002237884B2 - Anticancer treatment using triptolide prodrugs - Google Patents

Anticancer treatment using triptolide prodrugs Download PDF

Info

Publication number
AU2002237884B2
AU2002237884B2 AU2002237884A AU2002237884A AU2002237884B2 AU 2002237884 B2 AU2002237884 B2 AU 2002237884B2 AU 2002237884 A AU2002237884 A AU 2002237884A AU 2002237884 A AU2002237884 A AU 2002237884A AU 2002237884 B2 AU2002237884 B2 AU 2002237884B2
Authority
AU
Australia
Prior art keywords
alkyl
group
carbon
treatment
unbranched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002237884A
Other languages
English (en)
Other versions
AU2002237884A1 (en
Inventor
John M. Fidler
Ke Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmagenesis Inc
Original Assignee
Pharmagenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagenesis Inc filed Critical Pharmagenesis Inc
Publication of AU2002237884A1 publication Critical patent/AU2002237884A1/en
Application granted granted Critical
Publication of AU2002237884B2 publication Critical patent/AU2002237884B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2002237884A 2001-01-19 2002-01-18 Anticancer treatment using triptolide prodrugs Ceased AU2002237884B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/766,156 2001-01-19
US09/766,156 US6620843B2 (en) 2001-01-19 2001-01-19 Anticancer treatment using triptolide prodrugs
PCT/US2002/001650 WO2002056835A2 (en) 2001-01-19 2002-01-18 Anticancer treatment using triptolide prodrugs

Publications (2)

Publication Number Publication Date
AU2002237884A1 AU2002237884A1 (en) 2003-02-13
AU2002237884B2 true AU2002237884B2 (en) 2006-08-17

Family

ID=25075572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002237884A Ceased AU2002237884B2 (en) 2001-01-19 2002-01-18 Anticancer treatment using triptolide prodrugs

Country Status (8)

Country Link
US (1) US6620843B2 (enExample)
EP (1) EP1359909B1 (enExample)
JP (1) JP2004517882A (enExample)
AT (1) ATE406155T1 (enExample)
AU (1) AU2002237884B2 (enExample)
CA (1) CA2435322A1 (enExample)
DE (1) DE60228544D1 (enExample)
WO (1) WO2002056835A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243351B2 (en) * 2002-05-31 2009-04-30 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
CN100398544C (zh) * 2002-09-18 2008-07-02 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
WO2004058246A1 (en) * 2002-12-17 2004-07-15 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
US6943259B2 (en) * 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
US7820834B2 (en) * 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
WO2005077008A2 (en) * 2004-02-09 2005-08-25 Pharmagenesis, Inc. Methods for isolation of triptolide compounds from tripterygium wilfordii
ES2385716T3 (es) * 2004-03-02 2012-07-30 Pharmagenesis, Inc. Derivados en el anillo de lactona de triptolida como inmunomoduladores y agentes anticáncer
US20070244080A1 (en) * 2004-06-25 2007-10-18 Pharmagenesis, Inc. Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
US8617906B2 (en) 2004-10-13 2013-12-31 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
EP1946758A1 (en) * 2007-01-18 2008-07-23 Pierre Fabre Medicament Treatment of acute myeloid leukemia
WO2010030763A2 (en) 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
JP5653939B2 (ja) * 2009-02-05 2015-01-14 ファーマジェネシス， インコーポレイテッド 抗癌剤および免疫調節因子としてのトリプトリドｃ環誘導体
CN102596977B (zh) * 2009-05-07 2016-06-29 明尼苏达大学评议会 雷公藤内酯前药
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
US20130195896A1 (en) * 2010-04-07 2013-08-01 Steward Research And Specialty Projects Corporation Compositions and methods for the treatment of a neoplasia
US9846160B2 (en) 2012-02-27 2017-12-19 Board Of Regents, The University Of Texas Systems Ganglioside GD2 as a marker and target on cancer stem cells
WO2017136739A1 (en) * 2016-02-04 2017-08-10 The Johns Hopkins University Glucose conjugates of triptolide, analogs and uses thereof
CN107698653B (zh) * 2017-10-11 2019-08-27 中国农业科学院蜜蜂研究所 一种雷公藤甲素半抗原及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7093700A (en) * 1999-08-30 2001-03-26 Board Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005108A (en) 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6548537B1 (en) * 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
JP2002523495A (ja) 1998-09-02 2002-07-30 ファーマジェネシス， インコーポレイテッド 高い水溶性を有するトリプトリドプロドラッグ
EP1390358A4 (en) * 2001-03-15 2004-06-16 Pharmagenesis Inc AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNOMODULATORS AND ANTICROPHES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7093700A (en) * 1999-08-30 2001-03-26 Board Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent

Also Published As

Publication number Publication date
EP1359909B1 (en) 2008-08-27
EP1359909A4 (en) 2005-03-09
US20020099051A1 (en) 2002-07-25
WO2002056835A3 (en) 2003-02-27
WO2002056835A2 (en) 2002-07-25
US6620843B2 (en) 2003-09-16
CA2435322A1 (en) 2002-07-25
ATE406155T1 (de) 2008-09-15
JP2004517882A (ja) 2004-06-17
EP1359909A2 (en) 2003-11-12
DE60228544D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
US6620843B2 (en) Anticancer treatment using triptolide prodrugs
ES2273688T3 (es) Procedimiento y composicion para el tratamiento de cancer.
JP6501947B2 (ja) 抗腫瘍化合物
AU2002237884A1 (en) Anticancer treatment using triptolide prodrugs
JP2007509978A (ja) トコフェロール修飾治療薬化合物
JP2021147340A (ja) 化合物、そのナノ粒子及び癌疾患の治療剤
EP3858836A1 (en) Compound and use thereof
EP2254570B1 (en) Combination comprising paclitaxel for treating ovarian cancer
CN102731517A (zh) 喜树碱衍生物、其制备方法及其在制备治疗肿瘤药物中的应用
US9937261B2 (en) Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
JP2019513812A (ja) 化学療法の改善
BR112021005104A2 (pt) formulação de injeção intratumoral
CN117157281A (zh) 1,2,4,5-四噁烷化合物的靶向递送及其用途
AU2021239224A1 (en) Use of butylphthalide and derivative thereof
CN104080449A (zh) 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法
KR102694803B1 (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
ES2390801T3 (es) Procedimiento para el tratamiento de la neoplasia con una combinación de agentes quimioterápicos y radiación
CN106924225A (zh) 厚朴酚在制备抗肿瘤药物增敏剂中的应用
Hao et al. Novel fluorinated docetaxel analog for anti-hepatoma: Molecular docking and biological evaluation
WO2022250013A1 (ja) 抗腫瘍剤
CN117700419A (zh) 一氧化氮供体型咔唑衍生物及其在治疗肿瘤疾病中的用途
Tang et al. Synthesis and pharmacological evaluation of natural product Diphyllin derivatives against head and neck squamous cell carcinoma
JPH02304058A (ja) キサントシリンｘモノメチルエーテル誘導体及びそれを含有する抗腫瘍剤
CN113599370B (zh) 8-oh-dpat及其衍生物在制备抗肿瘤药物中的应用
US20040204435A1 (en) Alternating treatment with topoisomerase I and topoisomerase II inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired